Repro Med Systems, Inc. (KRMD)
| Previous Close | 2.7400 |
| Open | 2.7500 |
| Bid | 2.0300 x 900 |
| Ask | 4.0000 x 800 |
| Day's Range | 2.7500 - 2.8950 |
| 52 Week Range | 2.3000 - 4.9400 |
| Volume | |
| Avg. Volume | 183,575 |
| Market Cap | 128.516M |
| Beta (5Y Monthly) | 0.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0990 |
| Earnings Date | Mar. 21, 2022 - Mar. 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.67 |
- Simply Wall St.
Those who invested in Repro Med Systems (NASDAQ:KRMD) five years ago are up 523%
It might be of some concern to shareholders to see the Repro Med Systems, Inc. ( NASDAQ:KRMD ) share price down 16% in...
- Business Wire
KORU Medical Systems Receives FDA 510(k) Clearance for the Use of the FREEDOM60® with Two Additional SCIg Drugs
CHESTER, N.Y., December 21, 2021--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced FDA 510(k) clearance that expands on-label use of the FREEDOM60 Infusion System to two additional subcutaneous Ig (SCIg) medications, Cutaquig®, manufactured by Octapharma, and Xembify®, manufactured by Grifols.
- Business Wire
KORU Medical Systems to Unveil Updated Strategic Plan at Investor Day
CHESTER, N.Y., December 01, 2021--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced it will host an investor day to provide an update to its strategic plan.
